JPWO2021185361A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021185361A5
JPWO2021185361A5 JP2022556114A JP2022556114A JPWO2021185361A5 JP WO2021185361 A5 JPWO2021185361 A5 JP WO2021185361A5 JP 2022556114 A JP2022556114 A JP 2022556114A JP 2022556114 A JP2022556114 A JP 2022556114A JP WO2021185361 A5 JPWO2021185361 A5 JP WO2021185361A5
Authority
JP
Japan
Prior art keywords
mutation
mutein
sequence
amino acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518434A5 (https=
JP2023518434A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/081840 external-priority patent/WO2021185361A1/zh
Publication of JP2023518434A publication Critical patent/JP2023518434A/ja
Publication of JP2023518434A5 publication Critical patent/JP2023518434A5/ja
Publication of JPWO2021185361A5 publication Critical patent/JPWO2021185361A5/ja
Pending legal-status Critical Current

Links

JP2022556114A 2020-03-19 2021-03-19 インターロイキン２変異体およびその使用 Pending JP2023518434A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010197740 2020-03-19
CN202010197740.4 2020-03-19
CN202110266549.5 2021-03-11
CN202110266549 2021-03-11
PCT/CN2021/081840 WO2021185361A1 (zh) 2020-03-19 2021-03-19 白介素2突变体及其用途

Publications (3)

Publication Number Publication Date
JP2023518434A JP2023518434A (ja) 2023-05-01
JP2023518434A5 JP2023518434A5 (https=) 2024-04-02
JPWO2021185361A5 true JPWO2021185361A5 (https=) 2024-04-02

Family

ID=77770497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556114A Pending JP2023518434A (ja) 2020-03-19 2021-03-19 インターロイキン２変異体およびその使用

Country Status (9)

Country Link
US (1) US20230145766A1 (https=)
EP (1) EP4122952A4 (https=)
JP (1) JP2023518434A (https=)
KR (1) KR20220155316A (https=)
CN (1) CN115698052A (https=)
AU (1) AU2021239225B2 (https=)
CA (1) CA3175717A1 (https=)
TW (1) TWI790573B (https=)
WO (1) WO2021185361A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020057646A1 (zh) 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
EP3854805A4 (en) 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
AU2021237518B2 (en) * 2020-03-19 2024-08-15 Fortvita Biologics (Singapore) Pte.Ltd. Interleukin-2 mutant and use thereof
CN114380919B (zh) * 2020-10-18 2024-06-25 北京志道生物科技有限公司 经修饰的il-2分子及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20240082364A (ko) * 2021-09-22 2024-06-10 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 인터루킨-2 돌연변이 및 이의 융합 단백질
WO2023169524A1 (zh) * 2022-03-10 2023-09-14 广东菲鹏制药股份有限公司 白细胞介素2突变体以及含有其的复合物
CA3259108A1 (en) 2022-06-16 2023-12-21 Cephalon Llc Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses
CN119365482A (zh) * 2022-06-17 2025-01-24 舒泰神（北京）生物制药股份有限公司 白介素-2(il-2)突变体及其用途
TW202402784A (zh) * 2022-07-06 2024-01-16 中國商科望（上海）生物醫藥科技有限公司 Il2突變蛋白及其用途
CN118620056A (zh) * 2023-03-09 2024-09-10 北京天广实生物技术股份有限公司 Il-2变体及其用途
CN118680877A (zh) * 2023-03-21 2024-09-24 信达生物制药(苏州)有限公司 抗pd-1与突变il-2免疫缀合物制剂
CN117116336B (zh) * 2023-10-18 2024-01-23 深圳新锐基因科技有限公司 基于内部原子波动改善蛋白结构柔性弱点的方法和装置
US20250195677A1 (en) * 2023-12-19 2025-06-19 Cephalon Llc Uses for attenuated il-2 immunoconjugates
WO2026012466A1 (en) * 2024-07-12 2026-01-15 Vibrant Pharma Limited Interleukin-2 muteins and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
BRPI0508470A (pt) * 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
JP7637415B2 (ja) * 2018-06-22 2025-02-28 キュージーン インコーポレイテッド インターロイキン－２バリアントおよびその使用方法
EP3854805A4 (en) * 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
AU2021237518B2 (en) * 2020-03-19 2024-08-15 Fortvita Biologics (Singapore) Pte.Ltd. Interleukin-2 mutant and use thereof
KR20240082364A (ko) * 2021-09-22 2024-06-10 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 인터루킨-2 돌연변이 및 이의 융합 단백질

Similar Documents

Publication Publication Date Title
CN115698052A (zh) 白介素2突变体及其用途
JPWO2021185361A5 (https=)
ES2327409T3 (es) Proteinas de fusion fc mejoradas.
JP5077924B2 (ja) 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物
JP2015531751A (ja) 選択的対である軽鎖および重鎖を含む免疫グロブリン構築物
CN110914307A (zh) 改进的双特异性多肽分子
KR20020026558A (ko) 키메라성 폴리펩타이드, 이의 제조 방법 및 용도
JPH10501131A (ja) オンコスタチンｍ受容体
CN112236448B (zh) 用包含NC-1-Fc的蛋白寡聚体治疗血管发生、纤维化和癌症相关疾病的手段和方法
EP4303231A1 (en) Bispecific antibody
AU2022263441A1 (en) Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
KR101963230B1 (ko) 복수개의 단일 항체를 포함하는 단백질 복합체
KR20140036905A (ko) 이중특이 항체를 포함하는 단백질 복합체
JPWO2020037150A5 (https=)
JPWO2021185362A5 (https=)
CN107082815A (zh) 一种fsh‑hsa融合蛋白及其制备方法
CN116444622A (zh) 一种多肽、融合蛋白及其应用
JPWO2022133592A5 (https=)
JPWO2023070056A5 (https=)
JPH05304991A (ja) Ｉｌ−２受容体重鎖に結合するポリペプチド
JPWO2021168194A5 (https=)
JPWO2019213446A5 (https=)
JP7829127B2 (ja) 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質
JPWO2019213442A5 (https=)
JPH0380096A (ja) モチリン様ポリペプチドの製法並びにそのための組換えｄｎａ及び発現用プラスミド